Ronald Martell to join Cytori board of directors
Mr. Martell has more than 25 years' experience building and managing unique businesses in the biotech industry, and most recently served as Chief Executive Officer at Sevion Therapeutics, prior to which he held similar roles at NeurogesX and at Poniard Pharmaceuticals.
Earlier in his career Mr. Martell served as Senior Vice President of Commercial Operations at ImClone Systems, where he built ImClone Systems' worldwide commercial operations and field sales force to market and commercialize Erbitux with partners Bristol-Myers Squibb and Merck KGaA.
Prior to joining ImClone Systems, Mr. Martell worked for more than 10 years at Genentech in a variety of leadership positions, the last of which was Group Manager, Oncology.
At Genentech, he was responsible for building the company's oncology franchise including the launch of Herceptin for metastatic HER-2 positive breast cancer and Rituxan for non-Hodgkin's lymphoma. ■
LATEST MOVES FROM California
- Banc of California names Doug Bowers as CEO
- Reed's appoints Stefan Freeman as interim CEO
- Heron Therapeutics appoints Robert E. Hoffman as CFO
- Penumbra appoints Bridget O'Rourke to board
- Adverum Biotechnologies adds Richard N. Spivey to board
More inside POST
Processing to resume at 10 JBS plants Companies